- The disease
- Locally advanced pancreatic cancer refers to tumours that cannot be surgically removed because they have grown into nearby blood vessels or structures, but have not yet spread to distant organs. It accounts for roughly one-third of all new pancreatic cancer diagnoses. Patients in this setting typically receive chemotherapy regimens such as FOLFIRINOX (a combination of four drugs: folinic acid, fluorouracil, irinotecan, and oxaliplatin) or gemcitabine-based regimens. Median survival outcomes in this setting remain poor despite available systemic therapies.
- What the asset is trying to do
- OncoSil consists of microparticles containing Phosphorus-32 (P-32), a radioactive isotope, designed to be injected directly into pancreatic tumour tissue. Once implanted, the microparticles deliver targeted beta radiation to surrounding cancer cells. This approach, known as brachytherapy, delivers localised radiation from within the tumour itself rather than via external beam radiation therapy. It is designed to be used alongside standard chemotherapy regimens rather than as a standalone treatment.
- What the trial is measuring, and why it matters
- The lead post-market study, OSPREY (NCT04493632), is an observational, prospective global registry targeting 500 patients, with a primary completion date of 2025-11-01 (per ClinicalTrials.gov NCT04493632). The TRIPP-FFX study (NCT05466799) is a Phase 2 randomised trial comparing FOLFIRINOX alone versus OncoSil added to FOLFIRINOX in locally advanced pancreatic adenocarcinoma, targeting 88 patients, with primary completion listed as 2026-01-26 (per ClinicalTrials.gov NCT05466799). An announcement dated 2026-06-08 states the TRIPP-FFX trial met its co-primary endpoints, and the trial was accepted for oral presentation at ESMO GI 2026 (per ASX announcement 2026-06-09).
- Efficacy benchmarks in this setting
- In locally advanced pancreatic cancer treated with FOLFIRINOX, published data from the LAPACT trial reported a progression-free survival (PFS) rate at 6 months as the primary endpoint; median overall survival was 24.2 months (Hammel et al, JAMA Oncology 2019). For gemcitabine plus nab-paclitaxel in locally advanced disease, median overall survival figures from published studies have ranged across different trial populations ( specific citation for locally advanced subgroup). Because the OSPREY registry and earlier OncoSil pilot studies are single-arm, observational, or early-phase in design, any figures from those studies are not statistically comparable to results from randomised controlled trials of approved regimens.
- Commercial context
- OncoSil holds CE Mark approval for use in the European Union and TGA approval in Australia, as noted in ASX announcements dated 2026-05-19. The company has disclosed that a US Food and Drug Administration (FDA) Humanitarian Device Exemption (HDE) application is in progress, with the company announcing it is progressing that submission (per ASX announcement 2026-06-08). No approved localised brachytherapy microparticle device specifically for pancreatic cancer is listed on the US market at the time of these announcements. No licensing deal values or manufacturing partnership terms have been publicly disclosed in the provided data. OncoSil is described as the company's single named asset across all available announcements.